NCT04366713 2023-02-10
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
Puma Biotechnology, Inc.
Phase 2 Completed
Puma Biotechnology, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Eli Lilly and Company
AEterna Zentaris